Pasar al contenido principal

DESCIFRANDO LA CAPACIDAD INMUNOREGULADORA DE VISTA EN EL INTESTINO HUMANO EN LA ENFERMEDAD INFLAMATORIA INTESTINAL

PID2023-148270OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE VALLADOLID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Biological variability of human intraepithelial lymphocytes throughout the human gastrointestinal tract in health and coeliac disease

  • Fiz-López, Aida
  • Prado-Santos, Ángel de
  • Arribas, Elisa
  • García-Alonso, Francisco Javier
  • Izquierdo, Sandra
  • Martín-Muñoz, Álvaro
  • Garrote, José Antonio
  • Arranz, Eduardo
  • Barrio, Jesús
  • Fernández-Salazar, Luis
  • Bernardo, David
[Background]: Intraepithelial lymphocytes are the first line of defence of the human intestinal immune system. Besides, their composition is altered on patients with coeliac disease (CD), so they are considered as biomarkers with utility on their diagnose and/or monitoring. Our aim is to address their variability through the human gastrointestinal tract in health and characterized them in further depth in the coeliac duodenum., [Methods]: Intraepithelial lymphocytes were isolated from human gastric, duodenal, ileal and colonic biopsies, then stained with specific antibodies and acquired by flow cytometry., [Results]: Our results confirmed that the profile of Intraepithelial lymphocytes change through the length of the human gastrointestinal tract. Besides and given the central role that Interleukin-15 (IL-15) elicits on CD pathogenesis; we also assessed the expression of its receptor revealing that there was virtually no functional IL-15 receptor on duodenal Intraepithelial lymphocytes. Nevertheless and contrary to our expectations, the active IL-15 receptor was not increased either on Intraepithelial lymphocytes from CD patients., [Conclusions]: IL-15 might require additional stimulus to activate intraepithelial lymphocytes. These findings may provide novel tools to aid on a CD diagnosis and/or monitoring, at the time that provide the bases to perform functional studies in order of getting a deeper insight in the specific function that Intraepithelial lymphocytes elicit on CD pathogenesis., This research was funded by Ministerio de Ciencia e Innovación, Spain, grant number PID2023-148270OB-I00, Programa Estratégico Instituto de Biología y Genética Molecular (IBGM Junta de Castilla y León. Ref. CVC8485) and the European Commission –NextGenerationEU (Regulation EU 2020/2094), through CSIC's Global Health Platform (PTI Salud Global)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tofacitinib downregulates JAK1 and JAK3 on human intestinal monocytes and macrophages without affecting dendritic cells phenotype or function

  • Arribas-Rodríguez, Elisa
  • Prado-Santos, Ángel de
  • Andrés, Beatriz de
  • Velayos, Benito
  • Barrio, Jesús
  • Romero, Alejandro
  • García-Alonso, Francisco Javier
  • Martín-Muñoz, Álvaro
  • Garrote, José Antonio
  • Arranz, Eduardo
  • Fernández-Salazar, Luis
  • Bernardo, David
[Background] Ulcerative colitis (UC) is an inflammatory disorder of the gastrointestinal tract. Although Tofacitinib, which inhibits the JAK1 and JAK3 signalling pathway, is approved to treat patients with UC, its specific mechanism of action remain elusive. Given the central role that conventional dendritic cells (cDC) elicit in gut homeostasis, we hypothesised that Tofacitinib acts modulating cDC function in UC., [Methods] Human biopsies were obtained from colon of controls, and patients with UC (active and quiescent). Lamina propria mononuclear cells (LPMC) were ex-vivo cultured in the presence/absence of Tofacitinib. The specific effect elicited over human intestinal cDC, monocytes and macrophages was assessed by flow cytometry. cDC were also enriched following Tofacitinib conditioning in order to assess its effect over naïve T-cells., [Results] Several human intestinal cDC, monocyte and macrophage subsets can be found in the human colon, with these cells being more similar between controls and patients with qUC referred to patients with aUC. Following ex-vivo culture, Tofacitinib downregulated JAK1 expression on intestinal monocytes from patients with both active and quiescent UC. As for macrophages, JAK1 was decreased on patients with active UC while JAK was downregulated on macrophages from patients with quiescent disease. Tofacitinib did not modulate the phenotype or function of human intestinal cDC., [Conclussion] Tofacitinib does not modulate the phenotype and function of human intestinal cDC in UC. On the contrary, it displays a differential capacity to modulate intestinal monocyte and macrophage phenotype. Future studies should address whether it also translates into a differential function of these cells., This study is financed by a Pfizer Independent Medical Grant (ID: 54211793) the Spanish Ministry of Science (PID2023-148270OB-I00) and Junta de Castilla y Leon (IR2021-UVA04, IR2020-1-UVA01). DB is also a member of the CSIC's Global health Platform (PTI Salud Global)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Restoration of the lamina propria duodenal immune infiltrate in gluten-free diet treated celiac patients despite persistent villous atrophy

  • Fiz-López, Aida
  • Prado, Ángel De
  • Arribas, Elisa
  • Hierro, Alejandro G. del
  • Castro, Carolina G. de
  • Izquierdo, Sandra
  • Martín-Muñoz, Álvaro
  • Corrales-Cruz, Daniel
  • Cuesta- Sancho, Sara
  • Garrote, José Antonio
  • Arranz, Eduardo
  • Fernández-Salazar, Luis
  • Bernardo, David
[Introduction] Although celiac disease (CD) current and only treatment is a life-long strict gluten-free diet (GFD), some patients suffer from persistent duodenal lesions despite years into the diet. Hence, we aimed to study the effect that the GFD elicits on the mucosal immune infiltrate from these patients., [Method] To that end, duodenal biopsies were collected from non-celiac controls and CD patients, both at diagnosis and after at least one year into the GFD. The profile of duodenal intraepithelial lymphocytes (lymphogram) and the lamina propria immune infiltrate were determined by spectral cytometry., [Results] At diagnosis, all CD patients had mucosal atrophy, a compatible lymphogram, and an expansion of lamina propria NK cells, innate lymphoid cells, B-cells, Treg and Tγδ cells, all of them expressing high levels of Fas, and Integrins α4 and β7. However, despite all GFD-treated patients had negative serology, 68.4% of them displayed persistent villous atrophy (Marsh score ≥ 3), while 73.3% had a compatible lymphogram. Nevertheless, despite such persistent atrophy, the lamina propria mucosal immune infiltrate was normalized in all GFD-treated patients. Besides, time on the GFD, but not the persistence of mucosal atrophy, correlated with an increased expression of gut-homing migration markers on lamina propria effector T-cells from these patients., [Conclusion] Hence, we hereby have proved how the lamina propria immune infiltrate, as opposed to intraepithelial lymphocytes, is normalized in GFD-treated CD patients despite persistent villous atrophy, suggesting that the epithelial layer may be the driver of such paradoxical persistent mucosal inflammation., This work was funded by the Spanish Ministry of Science (PID2023-148270OB-I00), Junta de Castilla y León (GRS 2232/A/2020, IR2020-1-UVA01, IR2021-UVA04). David Bernardo is also a member of the CSIC´s Global Health Platform (PTI Salud Global)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

High-Dimensional Immune Profiling of Human Retinal Detachment Samples Using Spectral Flow Cytometry: A Protocol for Intraocular Immunotyping

  • Molinero-Sicilia, Laura
  • Hierro, Alejandro G. del
  • Galindo-Cabello, Nadia
  • Redruello-Guerrero, Pablo
  • Pastor-Idoate, Salvador
  • Usategui-Martín, Ricardo
  • Bernardo, David
Retinal detachment (RD) disrupts the eye’s immune-privileged status, causing a local inflammatory response that contributes to adverse clinical outcomes, including proliferative vitreoretinopathy and suboptimal visual recovery. Comprehensive profiling of intraocular immune cells will offer mechanistic insights and support the development of personalized immunomodulatory strategies. Here, we describe a robust and standardized protocol for the collection and high-dimensional analysis of the intraocular immune infiltrate from patients undergoing RD surgery, using state-of-the-art spectral cytometry. Vitreous and retinal tissue samples were obtained during standard surgical procedures, without the need for additional invasive interventions. Our approach integrates two complementary protocols: one that enables selective isolation of immune cells by sorting for CD45+ populations, and a second one that applies a 39-color spectral cytometry panel to profile the general landscape of immune subpopulations. The panel can identify up to 62 distinct viable immune subsets per sample, along with their functional status, as it includes expression of 13 functional markers. Hence, we hereby detail sample preparation, staining, and acquisition workflow, as well as the gating strategy and essential steps necessary for reproducible immunophenotyping. Our protocol, which enables high-dimensional immune profiling from minimal biological material, provides a valuable platform for studying ocular inflammation in RD and other retinal diseases., This work was funded by the Spanish Ministry of Science (PID2023-148270OB-I00, PID2023-147958OB-I00, and PDC2023-145857-100), Instituto de Salud Carlos III (RD21/0002/0017 and RD24/0007/0008), and Junta de Castilla y León (IR2020-1-UVA01, IR2021-UVA04, GRS-2569/A/22, GSR-2744/A1/2023, GSR-2125/A2/2024, and GSR-3073/A1/2024). David Bernardo is also a member of the CSIC´s Global Health Platform (PTI Salud Global). Finally, additional support was provided by the Department of Education of the Junta de Castilla y León and FEDER Funds (Reference: CLU-2023-1-04)., Peer reviewed